Double-blind trial of naproxen and phenylbutazone in ankylosing spondylitis.
Open Access
- 1 February 1978
- journal article
- clinical trial
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 37 (1) , 85-88
- https://doi.org/10.1136/ard.37.1.85
Abstract
In a double-blind double-placebo crossover study naproxen (500-750 mg daily) was found to be equivalent to phenylbutazone (400-600 mg daily) in the control of disease activity in 20 patients suffering from ankylosing spondylitis during a two times 5-week trial period. No serious side effects were observed during the trial period. Gastric complaints occurred twice as often under phenylbutazone as under naproxen.Keywords
This publication has 10 references indexed in Scilit:
- Four new anti-inflammatory drugs: responses and variations.BMJ, 1976
- RETARDATION OF OSSIFICATION OF LUMBAR VERTEBRAL COLUMN IN ANKYLOSING-SPONDYLITIS BY MEANS OF PHENYLBUTAZONE1976
- Naproxen Metabolism in ManThe Journal of Clinical Pharmacology, 1975
- Ankylosing Spondylitis: Open Long‐Term and Double‐Blind Crossover Studies with NaproxenThe Journal of Clinical Pharmacology, 1975
- [A double blind comparison of naproxen and indomethacin on the after-midnight-pain of patients with morbus bechterew].1975
- Naproxen. A new non-hormonal anti-inflammatory agent. Studies in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1974
- Assessment of the flexibility of the lumbar spine. A pilot study in children and adolescents.1973
- Assessment Of The Flexibility Of The Lumbar SpineScandinavian Journal of Rheumatology, 1973
- Anti-inflammatory and analgetic properties of d-2-(6'-methoxy-2'-naphthyl)-propionic acid (naproxen).1971
- ANTI-INFLAMMATORY AND ANALGETIC PROPERTIES OF d-2-(6'-METHOXY-2'-NAPHTHYL)-PROPIONIC ACID (NAPROXEN)The Journal of Pharmacology and Experimental Therapeutics, 1971